Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Deferred tax asset — Capitalized R&D expenses by Year
Deferred tax asset — Capitalized R&D expenses ($M) ($M)
Moderna Deferred tax asset — Capitalized R&D expenses: $1,693M in FY2025, down 5.6% from a year earlier.
Latest, FY2025
1,693
Period ended Dec 31, 2025
Change on a year earlier
-5.6%
1,794 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 15 (Income Taxes).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax asset — Capitalized R&D expenses ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,693 | -5.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 1,794 | +23.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 1,449 | +105.8% | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 704 | +245.1% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 204 | +1,357.1% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 14 | -29.6% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 19.9 | -10.0% | Form 10-K (filed 2021-02-26) ↗ |
| FY2018 | Dec 31, 2018 | 22.1 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Moderna Deferred tax asset — Capitalized R&D expenses ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/dta-cap-rd
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.